Skip to main content

You’ve been accepted to the Enhancing Oncology Model. Now what?

Doctor with stethoscope holding patient's hand

The Centers for Medicare and Medicaid Services Innovation Center recently announced approved applicants for the new Enhancing Oncology Model. If your facility has been selected by CMS, are you still weighing your options during the current baseline evaluation period? 

Two deciding factors may include the program data that CMS provides and whether EOM is enough of an improvement over the prior Oncology Care Model to make your investment worthwhile.

Another factor to consider: Will you have the resources in place to conduct a baseline evaluation before EOM’s program start on July 1, 2023?

How EOM differs from OCM

EOM aims to improve the coordination of oncology care, drive practice transformation and reduce Medicare fee-for-service spending through episode-based payment. It includes three major updates:

  • Fewer cancer types. Compared with OCM’s 21, EOM will be limited to seven common cancer types: breast, prostate, lung, small intestine/colorectal, multiple myeloma, lymphoma and chronic leukemia.
  • Revised baseline price prediction module. It now models prices separately for each of the seven cancer types. Additionally, the impact of comorbidities is modeled with increased specificity, the experience adjustment will take into account practice and regional variability, and the trend factor and novel therapy adjustments have been made cancer-type specific.
  • Immediate downside risk requirement. EOM requires participants to take on one of two downside risk arrangements immediately.

For more details on how EOM and OCM differ, read DataGen’s September blog. To see DataGen's key findings and in-depth analysis of EOM’s national baseline and prediction module methodology, watch our recorded webinar.

How to prepare

If these changes sound good, it’s time to prepare. DataGen recommends these five steps:

  1. Opt in to receive all program data. When CMS releases EOM participation agreements, opt in for all available data, which under OCM included claims-level data for specific episodes of care.
  2. Be ready to process data upon receipt. Have the internal resources or a contracted data vendor in place to begin baseline evaluation before EOM begins. CMS will provide data in the second quarter of 2023.
  3. Ensure clinical buy-in. If your practice has established EOM oncology stakeholders/physician champions, you’re more likely to be successful and navigate clinical changes well.
  4. Evaluate the target price. Can you deliver episode expenditures that are lower than model targets? Additional EOM differences may make that more likely, including underlying baseline prediction models, trend factors and novel therapy adjustments that are priced separately for each of the seven cancer types.
  5. Evaluate expenditures and utilization. Part D drugs, oncology care’s biggest cost driver, will be important. OCM risk adjustment didn’t control drug costs well or very much at all, but EOM’s design may assist your practice more.

How to decide

You become an official EOM participant after signing your participation agreement. This gives you time to evaluate any additional data that help with decision-making. You can stop participating with no risk, effective immediately, at any point prior to the model’s go-live date on July 1, 2023.

The practices that ultimately choose not to participate ­— including those that were a part of OCM — may not see EOM as enough of an improvement to make immediate downside financial risk worthwhile. Those that do participate generally believe they can succeed under the model and want to be at the forefront of oncology care and payment transformation.

Which group will you be in?

Need help with your EOM baseline evaluation? DataGen can provide key insight and consultation to help ensure the best performance, locking in better patient and financial outcomes and ensuring program success.


Popular posts from this blog

What does healthcare improvement look like in 2024 and beyond?

The healthcare industry has faced many new challenges in recent years. How does this seemingly ever-changing landscape impact healthcare improvement in 2024 and beyond? Based on the Institute for Healthcare Improvement 2023 Forum, quality improvement, safety and culture, equity and a functional delivery system remain top priorities across sectors. This was reflected in the forum agenda , which included 10 tracks and a scientific symposium with three primary focus areas: Quality: Addressing value, cost and quality; diagnostic excellence and improvement science Culture and safety: Building capability, leadership, workforce well-being and patient and workforce safety Patient focus: Equity, person-centered care and population health Since DataGen participated, we’ll give you some exclusive insight into what was discussed so you can better understand what’s driving healthcare in the new year. The future of healthcare improvement: 4 major insights 1. Quality requires a systems approach Th

Community Health Assessment Toolkit: Data Collection Methods

Why should you include data collection methods in your Community Health Assessment (CHA) toolkit? A CHA is like an electronic health record for a county, Metropolitan Statistical Area or region. Done well, the CHA captures clinical and social needs, informs options for new service delivery, facilitates collaboration among community stakeholders and ultimately can impact health outcomes.  Public health departments today must collect data on everything from diabetes outcomes to housing, income, immunizations and many other measures. Read on for the top methods for collecting the most challenging yet insightful data.  Community Health Assessment data collection methods  Like an EHR, the CHA includes defined components. The National Association of County and City Health Officials’ Mobilizing for Action through Planning and Partnerships (MAPP 2.0) model has several components and three assessments under the MAPP 2.0 model Mobilizing for Action through Planning and Partnerships Assessments: